Arrowhead Research Corp (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

6.12USD
26 May 2015
Change (% chg)

-- (--)
Prev Close
$6.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
340,098
52-wk High
$17.42
52-wk Low
$4.95

ARWR.OQ

Chart for ARWR.OQ

About

Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The... (more)

Overall

Beta: 2.25
Market Cap(Mil.): $364.13
Shares Outstanding(Mil.): 59.50
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 311.22 39.11
EPS (TTM): -1.56 -- --
ROI: -49.64 -5.48 15.56
ROE: -50.76 -6.48 16.57
Search Stocks

Deals of the day- Mergers and acquisitions

March 5 - The following bids, mergers, acquisitions and disposals were reported by 1430 GMT on Thursday:

05 Mar 2015

BRIEF-Arrowhead research acquires Novartis' RNAi R&D portfolio

* Acquires Novartis' entire RNAi research and development portfolio

05 Mar 2015

Arrowhead buys Novartis’ RNAi portfolio

- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins.

05 Mar 2015

Arrowhead buys Novartis' RNAi portfolio

March 5 - Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins.

05 Mar 2015

FDA places Arrowhead Hepatitis B drug on partial hold, shares plunge

- Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration placed the company's experimental hepatitis B treatment on partial clinical hold, seeking additional data from the drug's mid-stage study.

12 Jan 2015

UPDATE 1-FDA places Arrowhead Hep B drug on partial hold, shares plunge

Jan 12 - Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration placed the company's experimental hepatitis B treatment on partial clinical hold, seeking additional data from the drug's mid-stage study.

12 Jan 2015

FDA asks Arrowhead to cut Hep B drug dosage in mid-stage trial

Jan 12 - Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration asked the company to reduce the dosage of its experimental Hepatitis B treatment and requested additional data from the drug's mid-stage trial.

12 Jan 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$1,000.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks